These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25756697)

  • 1. Incidence of endometrial spotting or bleeding during continuous-combined estrogen-progestin therapy in postmenopausal women with and without hypertension.
    Sriprasert I; Beydoun H; Barnabei V; Nassir R; LaCroix AZ; Archer DF
    Menopause; 2015 Oct; 22(10):1067-75. PubMed ID: 25756697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
    Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
    Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A modern approach to postmenopausal HRT: trading bleeding with safety.
    Al-Azzawi F; Wahab M
    Womens Health (Lond); 2012 Jan; 8(1):1-4. PubMed ID: 22171766
    [No Abstract]   [Full Text] [Related]  

  • 4. Regulation of estrogen/progestogen receptors in the endometrium.
    Casper RF
    Int J Fertil Menopausal Stud; 1996; 41(1):16-21. PubMed ID: 8673152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen-progestin replacement therapy and endometrial cancer.
    Pike MC; Peters RK; Cozen W; Probst-Hensch NM; Felix JC; Wan PC; Mack TM
    J Natl Cancer Inst; 1997 Aug; 89(15):1110-6. PubMed ID: 9262248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simple method for determining the optimal dosage of progestin in postmenopausal women receiving estrogens.
    Padwick ML; Pryse-Davies J; Whitehead MI
    N Engl J Med; 1986 Oct; 315(15):930-4. PubMed ID: 3762595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.
    Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding.
    Yildirim G; Tugrul S; Uslu H; Pekin O; Eren S
    Arch Gynecol Obstet; 2006 Feb; 273(5):268-73. PubMed ID: 16315025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endometrial bleeding during hormone therapy: the effect of progestogens.
    Archer DF
    Maturitas; 2007 May; 57(1):71-6. PubMed ID: 17412535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultra low dose continuous combined hormone replacement therapy with 0.5mg 17beta-oestradiol and 2.5mg dydrogesterone: protection of the endometrium and amenorrhoea rate.
    Bergeron C; Nogales FF; Rechberger T; Tatarchjuk T; Zipfel L
    Maturitas; 2010 Jun; 66(2):201-5. PubMed ID: 20378287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gynecologic complications of cyclic estrogen progestin therapy.
    Ettinger B; Selby JV; Citron JT; Ettinger VM; Zhang D
    Maturitas; 1993 Nov; 17(3):197-204. PubMed ID: 8133794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transvaginal ultrasonographic measurement of endometrial thickness in postmenopausal women receiving estrogen replacement therapy.
    Holbert TR
    Am J Obstet Gynecol; 1997 Jun; 176(6):1334-8; discussion 1338-9. PubMed ID: 9215193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endometrial cancer risk in estrogen users after switching to estrogen-progestin therapy.
    Chubak J; Doherty JA; Cushing-Haugen KL; Voigt LF; Saltzman BS; Hill DA; Beresford SA; Weiss NS
    Cancer Causes Control; 2007 Nov; 18(9):1001-7. PubMed ID: 17653829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial morphology and bleeding patterns as a function of progestogen supplementation.
    Sturdee DW
    Int J Fertil Menopausal Stud; 1996; 41(1):22-8. PubMed ID: 8673153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen and progestogen effect on venous thromboembolism in menopausal women.
    Archer DF; Oger E
    Climacteric; 2012 Jun; 15(3):235-40. PubMed ID: 22612609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HRT dosing regimens: continuous versus cyclic-pros and cons.
    Shoupe D
    Int J Fertil Womens Med; 2001; 46(1):7-15. PubMed ID: 11294619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort.
    Lacey JV; Leitzmann MF; Chang SC; Mouw T; Hollenbeck AR; Schatzkin A; Brinton LA
    Cancer; 2007 Apr; 109(7):1303-11. PubMed ID: 17315161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
    Colditz GA; Hankinson SE; Hunter DJ; Willett WC; Manson JE; Stampfer MJ; Hennekens C; Rosner B; Speizer FE
    N Engl J Med; 1995 Jun; 332(24):1589-93. PubMed ID: 7753136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unscheduled bleeding in continuous combined hormone therapy users.
    Hickey M; Ameratunga D; Marino JL
    Maturitas; 2011 Dec; 70(4):400-3. PubMed ID: 22030385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer.
    Strom BL; Schinnar R; Weber AL; Bunin G; Berlin JA; Baumgarten M; DeMichele A; Rubin SC; Berlin M; Troxel AB; Rebbeck TR
    Am J Epidemiol; 2006 Oct; 164(8):775-86. PubMed ID: 16997897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.